Hesse, Christina
Beneke, Valerie
Konzok, Sebastian
Diefenbach, Claudia
Bülow Sand, Jannie Marie
Rønnow, Sarah Rank
Karsdal, Morten Asser
Jonigk, Danny
Sewald, Katherina
Braun, Armin
Leeming, Diana Julie
Wollin, Lutz http://orcid.org/0000-0002-3617-5772
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 26 November 2021
Accepted: 21 July 2022
First Online: 4 August 2022
Declarations
:
: The experiments with rat lung tissue were approved by the Animal Ethics Committee of the Danish Ministry of Justice (2011/561-2003, 2012-15-2934-00467). The experiments with human lung tissue were approved by the ethics committee of the Hannover Medical School (MHH, Hannover, Germany) and are in accordance with the Code of Ethics of the World Medical Association (renewed on 22.04.2015, number 2701-2015). All patients or their next of kin, caregivers or guardians gave written informed consent for using lung tissue for research. All information regarding the identity of the patients was anonymised.
: Not applicable.
: CH, VB, SK, DJ, KS and AB have nothing to declare. CD and LW are employees of Boehringer Ingelheim, the marketing authorisation holder of nintedanib used in this study. JMBS, SRR, MAK and DJL are full-time employees and stock owners at Nordic Bioscience. JMBS holds patent PRO-C6 assay (US20190309055A1; US20180088129A1). MAK is a patent- holder for assays for C1M (ref. 9359633 [US]), C3M (ref. 9359633 [US]) and PRO-C3 (ref. 9726674 [US]). DJL is a patent- holder for assays for this manuscript. Fraunhofer ITEM is a public, non-profit research organization who perform contract research on behalf of the pharmaceutical and biotech industry.